{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:35Z","timestamp":1792440635722,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"No special funding for this work"},{"DOI":"10.13039\/501100007512","name":"Universitat Rovira i Virgili","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007512","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of the Review<\/jats:title>\n            <jats:p>A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels.\u00a0This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes. The drug remains in circulation for less than 48\u00a0h, but its effect lasts for over six months. Two subcutaneous injections per year consistently lowers LDL-C by approximately 55% with a favorable safety profile. In combination with other LLTs, it can achieve LDL-C reductions of over 80%, supporting its role in high-intensity LLT strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Inclisiran represents a novel class of LLT. Administered biannually, reduces baseline LDL-C levels by half. Additionally, it has a strong safety profile. Due to its pharmacokinetic properties, is likely to improve adherence to LLT and persistently maintain low LDL-C levels.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11883-024-01271-x","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T02:14:27Z","timestamp":1736388867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field"],"prefix":"10.1007","volume":"27","author":[{"given":"Francesco","family":"Di Giacomo-Barbagallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Andreychuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonzalez-Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Ibarretxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"8","key":"1271_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","volume":"43","author":"A Timmis","year":"2022","unstructured":"Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. EurHeart J. 2022;43(8):716\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab892.","journal-title":"EurHeart J."},{"issue":"24","key":"1271_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962.","journal-title":"Eur Heart J"},{"issue":"23","key":"1271_CR3","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","volume":"76","author":"O Casta\u00f1er","year":"2020","unstructured":"Casta\u00f1er O, Pint\u00f3 X, Subirana I, Amor AJ, Ros E, Hern\u00e1ez \u00c1, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76(23):2712\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2020.10.008.","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"1271_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","journal-title":"Lancet."},{"issue":"1","key":"1271_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","volume":"8","author":"N Wang","year":"2020","unstructured":"Wang N, Fulcher J, Abeysuriya N, Park L, Kumar S, Di Tanna GL, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol. 2020;8(1):36\u201349. https:\/\/doi.org\/10.1016\/S2213-8587(19)30388-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"32","key":"1271_CR6","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J."},{"issue":"3","key":"1271_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","volume":"42","author":"J Schubert","year":"2021","unstructured":"Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42(3):243\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1011.","journal-title":"Eur Heart J"},{"issue":"22","key":"1271_CR8","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.jacc.2023.09.814","volume":"82","author":"G Mendieta","year":"2023","unstructured":"Mendieta G, Pocock S, Mass V, Moreno A, Owen R, Garc\u00eda-Lunar I, et al. Determinants of progression and regression of subclinical atherosclerosis over 6 years. J Am Coll Cardiol. 2023;82(22):2069\u201383. https:\/\/doi.org\/10.1016\/j.jacc.2023.09.814.","journal-title":"J Am Coll Cardiol"},{"key":"1271_CR9","doi-asserted-by":"publisher","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, et al; PACMAN-AMI collaborators. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","DOI":"10.1001\/jama.2022.5218"},{"issue":"7","key":"1271_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of evolocumab on coronary PlaquePhenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1271_CR11","doi-asserted-by":"publisher","unstructured":"P\u00e9rez de Isla L, D\u00edaz-D\u00edaz JL, Romero MJ, Mu\u00f1iz-Grijalvo O, Mediavilla JD, Arg\u00fceso R et al; SAFEHEART Study Group. Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study. Circulation. 2023;147(19):1436\u20131443. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062557.","DOI":"10.1161\/CIRCULATIONAHA.122.062557"},{"key":"1271_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106738","volume":"190","author":"L Masana","year":"2023","unstructured":"Masana L, Plana N, Andreychuk N, Ibarretxe D. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. Pharmacol Res. 2023;190: 106738. https:\/\/doi.org\/10.1016\/j.phrs.2023.106738.","journal-title":"Pharmacol Res"},{"key":"1271_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"G De Backer","year":"2019","unstructured":"De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner \u017d, Ryd\u00e9n L, et al. EUROASPIRE V collaborators; Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135\u201346. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.03.014.","journal-title":"Atherosclerosis"},{"key":"1271_CR14","doi-asserted-by":"crossref","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al; DA VINCI study. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u20131289.","DOI":"10.1093\/eurjpc\/zwaa047"},{"key":"1271_CR15","doi-asserted-by":"publisher","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. SANTORINI Study Investigators. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","DOI":"10.1016\/j.lanepe.2023.100624"},{"issue":"25","key":"1271_CR16","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"1271_CR17","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","DOI":"10.1056\/NEJMoa1615664"},{"issue":"22","key":"1271_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"1271_CR19","doi-asserted-by":"publisher","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u20131364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","DOI":"10.1056\/NEJMoa2215024"},{"key":"1271_CR20","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC Scientific Document Group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u2013188.","DOI":"10.1093\/eurheartj\/ehz455"},{"issue":"5","key":"1271_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022;36(5):549\u201371. https:\/\/doi.org\/10.1007\/s40259-022-00549-3.","journal-title":"BioDrugs"},{"issue":"6","key":"1271_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630\u201343. https:\/\/doi.org\/10.1038\/s41565-021-00898-0.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"1271_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jacl.2022.06.009","volume":"16","author":"D Soffer","year":"2022","unstructured":"Soffer D, Stoekenbroek R, Plakogiannis R. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering. J Clin Lipidol. 2022;16(5):574\u201382. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.009.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"1271_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002)","volume":"21","author":"G Tibolla","year":"2011","unstructured":"Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proproteinconvertase subtilisin\/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis. 2011;21(11):835\u201343. https:\/\/doi.org\/10.1016\/j.numecd.2011.06.002).","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"14","key":"1271_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jacc.2021.07.056","volume":"78","author":"C Oleaga","year":"2021","unstructured":"Oleaga C, Shapiro MD, Hay J, Mueller PA, Miles J, Huang C, et al. Hepatic sensing loop regulates PCSK9 secretion in response to inhibitory antibodies. JAm Coll Cardiol. 2021;78(14):1437\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.056.","journal-title":"JAm Coll Cardiol"},{"issue":"2","key":"1271_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","volume":"16","author":"D Kallend","year":"2022","unstructured":"Kallend D, Stoekenbroek R, He YL, Smith PF, Wijngaard P. Pharmacokinetics and pharmacodynamics of Inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208\u201319.","journal-title":"J Clin Lipidol"},{"key":"1271_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07413-0","author":"W Koenig","year":"2022","unstructured":"Koenig W, et al. Efficacy and safety of Inclisiran in patients with polyvascular disease: pooled, post Hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials. Cardiovasc Drugs Ther. 2022. https:\/\/doi.org\/10.1007\/s10557-022-07413-0.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1271_CR28","doi-asserted-by":"publisher","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. ORION-10 and ORION-11Investigators. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u20131519. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","DOI":"10.1056\/NEJMoa1912387"},{"key":"1271_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae109","author":"RS Wright","year":"2024","unstructured":"Wright RS, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024. https:\/\/doi.org\/10.1093\/cvr\/cvae109.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"1271_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032031","volume":"13","author":"MJ Wilkinson","year":"2024","unstructured":"Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA interference for cholesterol lowering: the bench-to-bedside story of Inclisiran. J Am Heart Assoc. 2024;13(6): e032031. https:\/\/doi.org\/10.1161\/JAHA.123.032031.","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"1271_CR31","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, et al. An \u201cInclisiran first\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2024;83(20):1939\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.382.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1271_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025551","volume":"11","author":"PP Toth","year":"2022","unstructured":"Toth PP, Bray S, Villa G, Palagashvili T, Sattar N, Stroes ESG, et al. Network Meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol. J Am Heart Assoc. 2022;11(18): e025551. https:\/\/doi.org\/10.1161\/JAHA.122.025551.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1271_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/03007995.2022.2049164","volume":"38","author":"H Burnett","year":"2022","unstructured":"Burnett H, Fahrbach K, Cichewicz A, Jindal R, Tarpey J, Durand A, et al. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022;38(5):777\u201384. https:\/\/doi.org\/10.1080\/03007995.2022.2049164.","journal-title":"Curr Med Res Opin"},{"key":"1271_CR34","unstructured":"Novartis. New long-term Leqvio\u00ae (Inclisiran) data from Novartis show sustained efficacy and safety over four years. 2023."},{"key":"1271_CR35","unstructured":"Novartis Pharmaceuticals. Study of Inclisiran to prevent cardiovascular (CV) events in participants with established cardiovascular disease (VICTORION-2P). ClinicalTrials.gov. 2023."},{"key":"1271_CR36","unstructured":"Novartis Pharmaceuticals. Coronary computed tomography study to assess the effect of Inclisiran in addition to maximally tolerated statin therapy on atherosclerotic plaque progression in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (V-PLAQUE)). ClinicalTrials.gov. 2023."},{"key":"1271_CR37","doi-asserted-by":"publisher","unstructured":"Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS; ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129\u2013138. https:\/\/doi.org\/10.1093\/eurheartj\/ehac594.14.","DOI":"10.1093\/eurheartj\/ehac594.14"},{"issue":"2","key":"1271_CR38","doi-asserted-by":"publisher","first-page":"e002184","DOI":"10.1136\/openhrt-2022-002184","volume":"9","author":"P Padam","year":"2022","unstructured":"Padam P, Barton L, Wilson S, David A, Walji S, de Lorenzo F, et al. Lipid lowering with Inclisiran: a real-world single-centre experience. Open Heart. 2022;9(2):e002184. https:\/\/doi.org\/10.1136\/openhrt-2022-002184.","journal-title":"Open Heart."},{"issue":"24","key":"1271_CR39","doi-asserted-by":"publisher","first-page":"00186","DOI":"10.1016\/j.jacl.2024.05.003","volume":"S1933\u20132874","author":"I Naoum","year":"2024","unstructured":"Naoum I, Saliba W, Aker A, Zafrir B. Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service. J Clin Lipidol. 2024;S1933\u20132874(24):00186\u20137. https:\/\/doi.org\/10.1016\/j.jacl.2024.05.003.","journal-title":"J Clin Lipidol"},{"key":"1271_CR40","doi-asserted-by":"publisher","unstructured":"Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17(6):818\u2013827. https:\/\/doi.org\/10.1016\/j.jacl.2023.09.005.","DOI":"10.1016\/j.jacl.2023.09.005"},{"key":"1271_CR41","doi-asserted-by":"publisher","unstructured":"Makhmudova U, Schatz U, Perakakis N, Kassner U, Schumann F, Axthelm C, et al. German Inclisiran Network (GIN). High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-worldmulticenter setting in Germany. Clin Res Cardiol. 2023;112(11):1639\u20131649. https:\/\/doi.org\/10.1007\/s00392-023-02247-8.","DOI":"10.1007\/s00392-023-02247-8"},{"issue":"17","key":"1271_CR42","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/heartjnl-2020-318760","volume":"107","author":"C Packard","year":"2021","unstructured":"Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart. 2021;107(17):1369\u201375. https:\/\/doi.org\/10.1136\/heartjnl-2020-318760.","journal-title":"Heart"},{"key":"1271_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","volume":"325","author":"M Averna","year":"2021","unstructured":"Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99\u2013109. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.03.039.","journal-title":"Atherosclerosis"},{"key":"1271_CR44","doi-asserted-by":"publisher","unstructured":"Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokg\u00f6zo\u011flu LS et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2021;ehab718. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718.","DOI":"10.1093\/eurheartj\/ehab718"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01271-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01271-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01271-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:01:29Z","timestamp":1758798089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01271-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01271-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"19 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FDGB, RS, SP and NA have nothing to declare.  AGL has received fees for lectures or support to attending meeting from Sanofi, Ferrer, Novartis. DI receives fees for lectures from Novartis, Sanofi, Chiesi, Novartis, SOBI, Daiichi-Sankyo LM receives fees for lectures and advisory work from Chiesi, Novartis, Sanofi, Amarin, MSD, Daiichi-Sankio, Ultragenix, out of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"25"}}